TP53 and neoplasm: Drugs were also tested in two HCT-116 variants in which one allele of TP53 was modified to express a p53 mutation (R248W) that is associated with increased tumor aggressiveness in murine cancer models while the second allele is either maintained as wild-type or inactivated [HCT-116 p53R248W/+ (R248W/+) and HCT-116 p53R248W/− (R248W/−)].